BIOHOPE is developing a blood-based in vitro diagnosis test to personalize immunosuppressant therapy for Rheumatoid Arthritis under treatment with immunosuppressant drugs. This diagnostic kit been named Immunobiogram® (IMBG) – Arthritis.
Inmunobiogram® is being studied in Rheumatoid Arthritis under a comprehensive clinical plan program, which includes a first proof of concept clinical study in 100 patients (BH-Pilot) and a subsequent validation study
“BH-Arthritis” is a clinical study which aims to evaluate the feasibility and potential clinical utility of a specifically-developed Inmunobiogram® for Rheumatoid Arthritis. This first-in-clinic study is to be done in collaboration with the Rheumatology Unit of “Reina Sofía” Hospital (Córdoba) and “Maimonides Institute of Biomedical Research”.
Worldwide, the annual incidence of RA is approximately three cases per 10,000 population, and the prevalence rate is approximately 1%, increasing with age and peaking between the ages of 35 and 50.
Clinical course of RA is very variable. More frequently, it follows a pattern of exacerbations and remissions. Outcomes are variable; some patients experience a relatively self-limited disease, whereas others have a chronic progressive illness. While there is no cure for RA, therapy for RA has improved greatly in the past 30 years. Today, patients begin their treatment with disease-modifying anti-rheumatic drugs, or DMARDs, which slow the progression of the disease. DMARDs have greatly improved the symptoms, function and quality of life for patients with RA.
The following chart, named ‘TREAT-TO-TARGET’, more precisely summarizes the preferred strategy for treatment of RA. The primary goals in the treatment of RA are to control inflammation and slow or stop disease progression. Currently, setting the goal, as well as initiating and adapting the therapy, should be done as a shared decision with the patient.